- Home
- BIRD vs FBIO Comparison
BIRD vs FBIO Comparison
Compare BIRD & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- FBIO
- Stock Information
- Founded
- BIRD 2015
- FBIO 2006
- Country
- BIRD United States
- FBIO United States
- Employees
- BIRD N/A
- FBIO N/A
- Industry
- BIRD Apparel
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- FBIO Health Care
- Exchange
- BIRD Nasdaq
- FBIO Nasdaq
- Market Cap
- BIRD 89.7M
- FBIO 88.7M
- IPO Year
- BIRD 2021
- FBIO N/A
- Fundamental
- Price
- BIRD $6.36
- FBIO $3.59
- Analyst Decision
- BIRD Buy
- FBIO Strong Buy
- Analyst Count
- BIRD 2
- FBIO 2
- Target Price
- BIRD $11.00
- FBIO $16.50
- AVG Volume (30 Days)
- BIRD 76.8K
- FBIO 988.5K
- Earning Date
- BIRD 11-05-2025
- FBIO 08-14-2025
- Dividend Yield
- BIRD N/A
- FBIO N/A
- EPS Growth
- BIRD N/A
- FBIO N/A
- EPS
- BIRD N/A
- FBIO N/A
- Revenue
- BIRD $170,646,000.00
- FBIO $59,301,000.00
- Revenue This Year
- BIRD N/A
- FBIO $51.59
- Revenue Next Year
- BIRD $4.20
- FBIO $44.74
- P/E Ratio
- BIRD N/A
- FBIO N/A
- Revenue Growth
- BIRD N/A
- FBIO N/A
- 52 Week Low
- BIRD $3.93
- FBIO $1.33
- 52 Week High
- BIRD $14.56
- FBIO $3.72
- Technical
- Relative Strength Index (RSI)
- BIRD 37.74
- FBIO 81.28
- Support Level
- BIRD $6.28
- FBIO $2.79
- Resistance Level
- BIRD $6.81
- FBIO $3.08
- Average True Range (ATR)
- BIRD 0.41
- FBIO 0.24
- MACD
- BIRD 0.09
- FBIO 0.14
- Stochastic Oscillator
- BIRD 20.56
- FBIO 86.20
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.